A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung Cancer
Xing Yi Woo(Jackson Laboratory), Carol J. Bult(Whitehead Institute for Biomedical Research), Allen K. Simons(Jackson Laboratory), Edison T. Liu(Jackson Laboratory), James G. Peterson(Jackson Laboratory), Philip C. Mack(UC Davis Comprehensive Cancer Center), William Holland(Mayo Clinic in Florida), Brian J. Sanderson(Jackson Laboratory), Emily L. Jocoy(Jackson Laboratory), R. Krishna Murthy Karuturi(Jackson Laboratory), Grace A. Stafford(Jackson Laboratory), Carolyn Paisie(Jackson Laboratory), Mandy Chen(Jackson Laboratory), James Keck(Jackson Laboratory), Michael W. Lloyd(Smithsonian Institution), David R. Gandara(University of California, Davis), Margaret Bundy(Jackson Laboratory), Joshy George(Jackson Laboratory), Sergii Domanskyi(Jackson Laboratory), Anuj Srivastava(Baba Raghav Das Medical College), Rebekah A. Tsai(University of California, Davis), Regina Gandour‐Edwards(University of California, Davis), Stephen C. Grubb(Jackson Laboratory), Susan Airhart(The University of Texas MD Anderson Cancer Center), Joel H. Graber(Jackson Laboratory), Primo N. Lara(UC Davis Comprehensive Cancer Center), Neal Goodwin(Champions Oncology (United States)), Mingshan Cheng(Jackson Laboratory), Jonathan W. Riess(University of California Davis Medical Center), Margaret Chavaree(Maine Medical Center), Thomas H. Openshaw(Cape Cod Hospital), Steven B. Neuhauser(Jackson Laboratory), Clifford G. Tepper(University of California, Davis)
Cited by 20
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k